Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma

Leukemia

Volumn 29, Issue 8, 2015, Pages 1695-1701

  Hess, G ^a   Keller, U ^b   Scholz, C W ^c   Witzens Harig, M ^d   Atta, J ^e   Buske, C ^f   Kirschey, S ^a   Ruckes, C ^a   Medler, C ^a   Van Oordt, C ^a   Klapper, W ^g   Theobald, M ^a   Dreyling, M ^h  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f UNIVERSITY HOSPITAL ULM   (Germany)

^g UNIVERSITY OF KIEL   (Germany)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; GLUCOSE; LACTIC ACID; POTASSIUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TEMSIROLIMUS; TRIACYLGLYCEROL; ANTINEOPLASTIC AGENT; CHLORMETHINE DERIVATIVE; MONOCLONAL ANTIBODY; RAPAMYCIN;

ADD ON THERAPY; ADULT; AGED; ALLERGIC REACTION; ANGIONEUROTIC EDEMA; APHTHOUS STOMATITIS; ARTICLE; BODY WEIGHT DISORDER; BRAIN INFARCTION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CATHETER REMOVAL; CHEMOTHERAPY INDUCED ANEMIA; CHILL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONSTIPATION; COUGHING; CREATININE BLOOD LEVEL; DECREASED APPETITE; DEVICE INFECTION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; EPISTAXIS; ERYTHEMA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; FEVER; FOLLICULAR LYMPHOMA; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERTENSIVE CRISIS; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; HYPOKALEMIA; LACTATE BLOOD LEVEL; LEUKOPENIA; LIMB DISEASE; LIMB INFECTIVE VENOUS THROMBOSIS; LUNG EDEMA; LYMPHOCYTOPENIA; MALE; MANTLE CELL LYMPHOMA; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL CHEST PAIN; MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; OPEN STUDY; OROPHARYNX PAIN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POLYNEUROPATHY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; THORAX PAIN; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VEIN THROMBOSIS; VIRUS PNEUMONIA; VOMITING; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; FEASIBILITY STUDY; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; REMISSION; SAFETY; SURVIVAL RATE;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, FOLLICULAR; LYMPHOMA, MANTLE-CELL; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NITROGEN MUSTARD COMPOUNDS; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SAFETY; SIROLIMUS; SURVIVAL RATE;

EID: 84938965734     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.60     Document Type: Article

References (41)

1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
2. Hiddemann W, Dreyling M, Forstpointner R, Kneba M, Woermann B, Lengfelder E et al. Combined immunochemotherpy (R-CHOP) significantly improves time to treatment failure in first line therapy of follicular lymphoma. Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 2003; 102: 352a.
3. Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520-531.
4. Thomas DW, Owen RG, Johnson SA, Hillmen P, Seymour JF, Wolf MM et al. Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leuk Lymphoma 2005; 46: 549-552.
5. Lenz G, Dreyling M, Hoster E, Wormann B, Duhrsen U, Metzner B et al. Immu-nochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lym-phoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984-1992.
6. Advani R, Buggy J, Sharman J, Smith S, Boyd T, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88-94.
7. Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 370: 1008-1018.
8. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867-4874.
9. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622-1627.
10. Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Boni JP, Dukart G et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006; 12: 5755-5763.
11. Drakos E, Rassidakis GZ, Medeiros LJ. Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas. Expert Rev Mol Med 2008; 10: e4.
12. Peponi E, Drakos E, Reyes G, Leventaki V, Rassidakis GZ, Medeiros LJ. Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma. Am J Pathol 2006; 169: 2171-2180.
13. Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347-5356.
14. Ansell SM, Inwards DJ, Rowland KM Jr, Flynn PJ, Morton RF, Moore DF Jr et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008; 113: 508-514.
15. Renner C, Zinzani PL, Gressin R, Klingbiel D, Dietrich PY, Hitz F et al. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012; 97: 1085-1091.
16. Hess G, Romaguera J, Verhoef G, Herbrecht R, Crump M, Strahs A et al. Phase III study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice therapy. J Clin Oncol 2008; 27: 3822-3829, (May 20 suppl; abstr 8513).
17. Hess G. Temsirolimus for the treatment of mantle cell lymphoma. Expert Rev Hematol 2009; 2: 631-640.
18. Smith SM, van Besien K, Karrison T, Dancey J, McLaughlin P, Younes A et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010; 28: 4740-4746.
19. Farag SS, Zhang S, Jansak BS, Wang X, Kraut E, Chan K et al. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res 2009; 33: 1475-1480.
20. Wang L, Shi WY, Wu ZY, Varna M, Wang AH, Zhou L et al. Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma. J Hematol Oncol 2010; 3: 30.
21. Kiewe P, Thiel E. Impressive response to temsirolimus in a patient with chemotherapy refractory diffuse large B-cell non-Hodgkin's lymphoma. Ann Hematol 2011; 90: 109-110.
22. Ansell SM, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011; 12: 361-368.
23. Inwards DJ, Fishkin P, LaPlant BR, Drake MT, Kurtin P, Nikcevich D et al. Phase I trial of Rituximab, Cladribine and Temsirolimus (RCT) for initial therapy of mantle cell lymphoma. ASH Annu Meeting Abstr 2012; 120: 3661.
24. Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383-3389.
25. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210.
26. Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4473-4479.
27. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
28. Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011; 43: 830-837.
29. Visco C, Finotto S, Zambello R, Paolini R, Menin A, Zanotti R et al. Combination of Rituximab, Bendamustine, and Cytarabine for patients with mantle-cell non-hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 2013; 31: 1442-1449.
30. Weide R, Hess G, Koppler H, Heymanns J, Thomalla J, Aldaoud A et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pre-treated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007; 48: 1299-1306.
31. Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011; 117: 2807-2812.
32. Rigacci L, Puccini B, Cortelazzo S, Gaidano G, Piccin A, D'Arco A et al. Bend-amustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients. Ann Hematol 2012; 91: 1013-1022.
33. Ahmadi T, Chong EA, Gordon A, Aqui NA, Nasta SD, Svoboda J et al. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. Cancer 2014; 120: 222-228.
34. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012; 13: 716-723.
35. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507-516.
36. Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu SS et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia 2013; 27: 1902-1909.
37. Wang M, Hagemeister F, Westin J, Fayad L, Samaniego F, Turtorro F et al. Ibrutinib and Rituximab are an efficacious and safe combination in relapsed mantle cell lymphoma: preliminary results from a phase ii clinical trial. ASH Annu Meeting Abstr 2014 (abstract 627).
38. Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR et al. A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood 2014; 123: 3398-3405.
39. Trneny M, Lamy T, Walewski J, Jurczak W, Belada D, Mayer J et al. Phase II randomized, multicenter study of lenalidomide vs best investigator's choice in relapsed/refractory mantle cell lymphoma: results of the MCL-002 (SPRINT) Study. ASH Annu Meeting Abstr. 2014 (abstract 626).
40. Zaja F, De Luca S, Vitolo U, Orsucci L, Levis A, Salvi F et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012; 97: 416-422.
41. Lamm W, Kaufmann H, Raderer M, Hoffmann M, Chott A, Zielinski C et al. Bor-tezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 2011; 96: 1008-1014.